Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

MTCT rate according to age, feeding mode, treatment, and prophylaxis regimens.

Sokhna Bousso Gueye (6718586)
Halimatou Diop-Ndiaye (428178)
Ousmane Diouf (1904476)
Aissatou Sow-Ndoye (6718589)
Fatoumata Touré (4898905)
Ndèye Fatou Ngom-Faye (6718592)
Diabou Diagne-Gueye (6718595)
Khady Mbow-Ndiaye (6718598)
Papa Amadou Niang Diallo (6718601)
Aïssatou Gaye-Diallo (6718604)
Souleymane Mboup (163882)
Cheikh Tidiane Ndour (5770673)
Cheikh Saad-Bouh Boye (6718607)
Coumba Touré-Kane (4109935)

May 2019

MTCT rate according to age, feeding mode, treatment, and prophylaxis regimens.</p

Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of confirmed VL cases, per year under intervention.

Orin Courtenay (103643)
Ahad Bazmani (6421370)
Parviz Parvizi (6421373)
Paul D. Ready (831582)
Mary M. Cameron (6421376)

March 2019

Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of confirmed VL case...

Mean and Interquartile Range of Raw HbA1c Testing Rates in 2010, by Decile of Estimated Rates in 2009.

Laura C. Yasaitis (652482)
Thomas Bubolz (652483)
Jonathan S. Skinner (652484)
Amitabh Chandra (222113)

October 2014

Mean and Interquartile Range of Raw HbA1c Testing Rates in 2010, by Decile of Estimated Rates in ...

Fitted average monthly VMMC rates per 100 HTS, by study condition, over entire study period and within the first six months of intervention implementation, intent-to-treat and per-protocol samples.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

Fitted average monthly VMMC rates per 100 HTS, by study condition, over entire study period and with...

Fitted average monthly VMMC rates per 100 HTS.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

VMMC + SS months are split into those where women’s groups were conducted vs. those where only men’s...

Analysis of the effects of the interventions on uptake of VMMC three months after enrollment.

Jonathan M. Grund (4495348)
Frankline Onchiri (4495333)
Edward Mboya (4495336)
Faith Ussery (7326047)
Paul Musingila (4495330)
Spala Ohaga (4495351)
Elijah Odoyo-June (302394)
Naomi Bock (338509)
Benard Ayieko (14564216)
Kawango Agot (221000)

February 2023

Analysis of the effects of the interventions on uptake of VMMC three months after enrollment.</p

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in the protocol period 12 months before study start and the 18-month CQI period.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in...

Average monthly pharmaceutical prescriptions per patient before, during and after the reform announcement and variation rates.

Cristina Hernández-Izquierdo (6519347)
Beatriz González López-Valcárcel (3242571)
Stephen Morris (324510)
Mariya Melnychuk (4896802)
Ignacio Abásolo Alessón (6065702)

March 2019

Average monthly pharmaceutical prescriptions per patient before, during and after the reform announc...

Patient median Hb coefficients of variation and median Hb ranges for two 6-month periods before and three 6-month periods after the start of the CQI process.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Patient median Hb coefficients of variation and median Hb ranges for two 6-month periods before a...

Intervention dose prescribed and adherence over the 12 month study period.

Catherine Sherrington (624773)
Stephen R. Lord (385500)
Constance M. Vogler (624774)
Jacqueline C. T. Close (624775)
Kirsten Howard (137555)
Catherine M. Dean (624776)
Gillian Z. Heller (624777)
Lindy Clemson (624778)
Sandra D. O'Rourke (624779)
Elisabeth Ramsay (624780)
Elizabeth Barraclough (624781)
Robert D. Herbert (624782)
Robert G. Cumming (341277)

September 2014

Intervention dose prescribed and adherence over the 12 month study period.</p

The average weekly consumption recorded during the pre-treatment, treatment and post-treatment periods, within the 0.005% and 0.01% warfarin-treated plots and the control plot.

Richard M. Poché (4759524)
David Poché (3477380)
Greg Franckowiak (5942549)
Daniel J. Somers (5942552)
Lindsay N. Briley (5942555)
Batchimeg Tseveenjav (5942558)
Larisa Polyakova (3477377)

November 2018

The average weekly consumption recorded during the pre-treatment, treatment and post-treatment perio...

Incidence rates of bleeding events stratified by time since start of VKA treatment.

Nienke van Rein (562335)
Willem M. Lijfering (3389438)
Mettine H. A. Bos (3389441)
Martien H. Herruer (3389447)
Helga W. Vermaas (3389444)
Felix J. M. van der Meer (728857)
Pieter H. Reitsma (320491)

December 2016

Incidence rates of bleeding events stratified by time since start of VKA treatment.</p

Average IPTp coverage during six-month periods pre- and post-intervention and difference-in-difference analysis.

Christian Rassi (2549743)
Georgia R. Gore-Langton (5725085)
Badru Gidudu Walimbwa (5725088)
Clare E. Strachan (3141420)
Rebecca King (2580442)
Sinwan Basharat (5725091)
Celine Christiansen-Jucht (5725094)
Kirstie Graham (2549725)
Sam Siduda Gudoi (3445691)

September 2018

Average IPTp coverage during six-month periods pre- and post-intervention and difference-in-differen...

Adjusted incidence rate ratios for intervention effects in access rates to HIV testing and treatment services over the 23 months of the intervention.

George Bello (41698)
Brian Faragher (52379)
Lifah Sanudi (716121)
Ireen Namakhoma (125890)
Hastings Banda (41699)
Rasmus Malmborg (3471020)
Rachael Thomson (3471017)
S. Bertel Squire (308149)

September 2017

Adjusted incidence rate ratios for intervention effects in access rates to HIV testing and treatm...

Time series of monthly study outcomes in intervention and control clinics and their differences over time among established patients.

Dennis Ross-Degnan (386696)
John Chalker (3437300)
Jafary Liana (3337371)
Mwikemo Deborah Kajoka (4476631)
Richard Valimba (3337377)
Suleiman Kimatta (3337365)
Angel Dillip (32773)
Catherine Vialle-Valentin (3337368)
Martha Embrey (3184980)
Rachel Lieber (3337386)
Keith Johnson (2114893)

September 2017

The figures present the monthly values of the eight study outcomes from August 2014 until March 2...

MTCT rate according to age, feeding mode, treatment, and prophylaxis regimens.

Sokhna Bousso Gueye (6718586)
Halimatou Diop-Ndiaye (428178)
Ousmane Diouf (1904476)
Aissatou Sow-Ndoye (6718589)
Fatoumata Touré (4898905)
Ndèye Fatou Ngom-Faye (6718592)
Diabou Diagne-Gueye (6718595)
Khady Mbow-Ndiaye (6718598)
Papa Amadou Niang Diallo (6718601)
Aïssatou Gaye-Diallo (6718604)
Souleymane Mboup (163882)
Cheikh Tidiane Ndour (5770673)
Cheikh Saad-Bouh Boye (6718607)
Coumba Touré-Kane (4109935)

May 2019

MTCT rate according to age, feeding mode, treatment, and prophylaxis regimens.</p

Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of confirmed VL cases, per year under intervention.

Orin Courtenay (103643)
Ahad Bazmani (6421370)
Parviz Parvizi (6421373)
Paul D. Ready (831582)
Mary M. Cameron (6421376)

March 2019

Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of confirmed VL case...

Mean and Interquartile Range of Raw HbA1c Testing Rates in 2010, by Decile of Estimated Rates in 2009.

Laura C. Yasaitis (652482)
Thomas Bubolz (652483)
Jonathan S. Skinner (652484)
Amitabh Chandra (222113)

October 2014

Mean and Interquartile Range of Raw HbA1c Testing Rates in 2010, by Decile of Estimated Rates in ...

Fitted average monthly VMMC rates per 100 HTS, by study condition, over entire study period and within the first six months of intervention implementation, intent-to-treat and per-protocol samples.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

Fitted average monthly VMMC rates per 100 HTS, by study condition, over entire study period and with...

Fitted average monthly VMMC rates per 100 HTS.

Stephen M. Weiss (6804122)
Kasonde Bowa (2813896)
Robert Zulu (16813963)
Violeta J. Rodriguez (3174705)
Ryan R. Cook (8812859)
Deborah L. Jones (3174693)

January 2024

VMMC + SS months are split into those where women’s groups were conducted vs. those where only men’s...

Analysis of the effects of the interventions on uptake of VMMC three months after enrollment.

Jonathan M. Grund (4495348)
Frankline Onchiri (4495333)
Edward Mboya (4495336)
Faith Ussery (7326047)
Paul Musingila (4495330)
Spala Ohaga (4495351)
Elijah Odoyo-June (302394)
Naomi Bock (338509)
Benard Ayieko (14564216)
Kawango Agot (221000)

February 2023

Analysis of the effects of the interventions on uptake of VMMC three months after enrollment.</p

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in the protocol period 12 months before study start and the 18-month CQI period.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

For all study patients, patient median Hb, median TSAT, mean IV iron and mean EPO administered in...

Average monthly pharmaceutical prescriptions per patient before, during and after the reform announcement and variation rates.

Cristina Hernández-Izquierdo (6519347)
Beatriz González López-Valcárcel (3242571)
Stephen Morris (324510)
Mariya Melnychuk (4896802)
Ignacio Abásolo Alessón (6065702)

March 2019

Average monthly pharmaceutical prescriptions per patient before, during and after the reform announc...

Patient median Hb coefficients of variation and median Hb ranges for two 6-month periods before and three 6-month periods after the start of the CQI process.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Patient median Hb coefficients of variation and median Hb ranges for two 6-month periods before a...

Intervention dose prescribed and adherence over the 12 month study period.

Catherine Sherrington (624773)
Stephen R. Lord (385500)
Constance M. Vogler (624774)
Jacqueline C. T. Close (624775)
Kirsten Howard (137555)
Catherine M. Dean (624776)
Gillian Z. Heller (624777)
Lindy Clemson (624778)
Sandra D. O'Rourke (624779)
Elisabeth Ramsay (624780)
Elizabeth Barraclough (624781)
Robert D. Herbert (624782)
Robert G. Cumming (341277)

September 2014

Intervention dose prescribed and adherence over the 12 month study period.</p

The average weekly consumption recorded during the pre-treatment, treatment and post-treatment periods, within the 0.005% and 0.01% warfarin-treated plots and the control plot.

Richard M. Poché (4759524)
David Poché (3477380)
Greg Franckowiak (5942549)
Daniel J. Somers (5942552)
Lindsay N. Briley (5942555)
Batchimeg Tseveenjav (5942558)
Larisa Polyakova (3477377)

November 2018

The average weekly consumption recorded during the pre-treatment, treatment and post-treatment perio...

Incidence rates of bleeding events stratified by time since start of VKA treatment.

Nienke van Rein (562335)
Willem M. Lijfering (3389438)
Mettine H. A. Bos (3389441)
Martien H. Herruer (3389447)
Helga W. Vermaas (3389444)
Felix J. M. van der Meer (728857)
Pieter H. Reitsma (320491)

December 2016

Incidence rates of bleeding events stratified by time since start of VKA treatment.</p

Average IPTp coverage during six-month periods pre- and post-intervention and difference-in-difference analysis.

Christian Rassi (2549743)
Georgia R. Gore-Langton (5725085)
Badru Gidudu Walimbwa (5725088)
Clare E. Strachan (3141420)
Rebecca King (2580442)
Sinwan Basharat (5725091)
Celine Christiansen-Jucht (5725094)
Kirstie Graham (2549725)
Sam Siduda Gudoi (3445691)

September 2018

Average IPTp coverage during six-month periods pre- and post-intervention and difference-in-differen...

Adjusted incidence rate ratios for intervention effects in access rates to HIV testing and treatment services over the 23 months of the intervention.

George Bello (41698)
Brian Faragher (52379)
Lifah Sanudi (716121)
Ireen Namakhoma (125890)
Hastings Banda (41699)
Rasmus Malmborg (3471020)
Rachael Thomson (3471017)
S. Bertel Squire (308149)

September 2017

Adjusted incidence rate ratios for intervention effects in access rates to HIV testing and treatm...

Time series of monthly study outcomes in intervention and control clinics and their differences over time among established patients.

Dennis Ross-Degnan (386696)
John Chalker (3437300)
Jafary Liana (3337371)
Mwikemo Deborah Kajoka (4476631)
Richard Valimba (3337377)
Suleiman Kimatta (3337365)
Angel Dillip (32773)
Catherine Vialle-Valentin (3337368)
Martha Embrey (3184980)
Rachel Lieber (3337386)
Keith Johnson (2114893)

September 2017

The figures present the monthly values of the eight study outcomes from August 2014 until March 2...

MTCT rate according to age, feeding mode, treatment, and prophylaxis regimens.

Sokhna Bousso Gueye (6718586)
Halimatou Diop-Ndiaye (428178)
Ousmane Diouf (1904476)
Aissatou Sow-Ndoye (6718589)
Fatoumata Touré (4898905)
Ndèye Fatou Ngom-Faye (6718592)
Diabou Diagne-Gueye (6718595)
Khady Mbow-Ndiaye (6718598)
Papa Amadou Niang Diallo (6718601)
Aïssatou Gaye-Diallo (6718604)
Souleymane Mboup (163882)
Cheikh Tidiane Ndour (5770673)
Cheikh Saad-Bouh Boye (6718607)
Coumba Touré-Kane (4109935)

May 2019

MTCT rate according to age, feeding mode, treatment, and prophylaxis regimens.</p

Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of confirmed VL cases, per year under intervention.

Orin Courtenay (103643)
Ahad Bazmani (6421370)
Parviz Parvizi (6421373)
Paul D. Ready (831582)
Mary M. Cameron (6421376)

March 2019

Crude and adjusted clinical VL incidence risk ratios (IRR), and observed number of confirmed VL case...

Mean and Interquartile Range of Raw HbA1c Testing Rates in 2010, by Decile of Estimated Rates in 2009.

Laura C. Yasaitis (652482)
Thomas Bubolz (652483)
Jonathan S. Skinner (652484)
Amitabh Chandra (222113)

October 2014

Mean and Interquartile Range of Raw HbA1c Testing Rates in 2010, by Decile of Estimated Rates in ...

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

Abstract

Extracted data

Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

Abstract

Extracted data

Related items

Related items